Another variety first passed the consistency evaluation!

In the evening of August 22, Watson pharmaceutical released a corporate announcement, and its company was on August 22, 2019 China Pharmaceutical Co., Ltd became the first enterprise in China to apply for the supplementary application of aluminum magnesium carbonate chewable tablets according to the consistency evaluation of generic drugs As the first-line medicine for digestive system, the aluminum magnesium carbonate chewable tablet has the functions of anti acid, anti bile and protecting mucous membrane It can treat upper digestive tract diseases as a whole with three effects The product is suitable for the treatment of various stomach diseases: 1 Acute and chronic gastritis; 2 Gastric and duodenal ulcer; 3 Reflux esophagitis; 4 Stomach discomfort related to gastric acid, such as stomachache, heartburn, acid belching and fullness; 5 Prevention of gastric mucous membrane damage caused by non steroidal drugs It can be widely used in digestive department, emergency department, otolaryngology, neurology and other departments Its main drug, magnesium aluminocarbonate, is a crystalline powder insoluble in water, which has a layered network structure and is not absorbed by the gastrointestinal tract after oral administration, so it has high safety In addition, the company is the first domestic enterprise of aluminum and magnesium carbonate raw materials that has passed the DMF filing of the US FDA It has export qualification and realizes the integration of raw materials and preparations, with excellent quality and guaranteed supply Aluminocarbonate chewable tablets are recommended drugs in the consensus opinions on chronic gastritis in China and the consensus opinions on integrated diagnosis and treatment of traditional Chinese and Western medicine for peptic ulcer, and are listed in the national directory of basic drugs (2018 version) and the national directory of basic medical insurance, industrial injury insurance and maternity insurance drugs (2019 version) According to the pharmaceutical intelligence data, at present, there are 30 market approvals for domestic aluminum magnesium carbonate chewable tablets, more than 30 manufacturers, and only 6 enterprises participating in the consistency evaluation of the reference record It is worth mentioning that this product is an exempt be test drug At present, only the first application of Huasen pharmaceutical has been accepted, the first one has been approved, and the top one has been selected In addition, up to now, Huasen has applied for a total of 2 drugs for conformity assessment, both of which have passed the assessment, and the aluminum magnesium carbonate chewable tablet is the second one that has been assessed by the company See the following figure for details: